By Shahanoor Akter Chowdhury, MA, MSS, PHR consultant; Lindsey Green, MA, PHR senior program coordinator, Program on Sexual Violence in Conflict Zones; Linda Kaljee, PhD, senior research investigator, Henry Ford Health System, Global Health Initiative; Thomas McHale, SM, PHR deputy director, Program on Sexual Violence in Conflict Zones; and Ranit Mishori, MD, MSH, PHR senior medical advisor, professor of family medicine, Georgetown University School of Medicine.
In August 2017, the armed forces of Myanmar (Tatmadaw) unleashed a campaign of widespread and systematic attacks on the country’s Rohingya communities, escalating previous episodes of violent human rights abuses committed against the Rohingya population. The United Nations (UN) and multiple human rights groups documented that Myanmar security forces committed rape, gang rape, sexual slavery, forced nudity, genital mutilation and other forms of violence targeting sexual organs, sexual assault, and threats and attempts at
Vaccine trial participants who received placebo now hop the line for the real thing from Pfizer, Moderna Judy Peres, Chicago Tribune
Good news for tens of thousands of volunteers in the COVID-19 vaccine trials: Many of those who received a placebo are now being offered a vaccine in some cases, earlier than they would otherwise have been eligible.
Participants in Pfizer’s vaccine study some of whom had mounted a noisy campaign on social media have been advised that anyone who wants one can receive the first of two shots by March 1. Participants in Moderna’s vaccine trial are already getting immunized.
English Analysis on United States of America about Health, Protection and Human Rights, Epidemic and more; published on 12 Jan 2021 by Physicians for Human Rights
Blueprint Medicines Announces R&D Leadership Transitions Becker Hewes, M.D., promoted to Chief Medical Officer Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company s research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral, M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and biostatistics. In his new